A BILL 
To provide patient protections with respect to the cost of 
insulin. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Insulin Price Reduc-
4
tion Act’’. 
5
SEC. 2. INSULIN PRICE PROTECTIONS. 
6
(a) IN GENERAL.—Subpart II of part A of title 
7
XXVII of the Public Health Service Act (42 U.S.C. 
8
15:51 Nov 02, 2019
H4906
2 
•HR 4906 IH
300gg–11 et seq.) is amended by adding at the end the 
1
following: 
2
‘‘SEC. 2729A. INSULIN PRICE PROTECTIONS. 
3
‘‘(a) CONTRACTING REQUIREMENTS.— 
4
‘‘(1) IN GENERAL.— 
5
‘‘(A) REQUIREMENT.—Except as provided 
6
in subparagraph (B), a group health plan or a 
7
health insurance issuer offering group or indi-
8
vidual health insurance coverage shall not, and 
9
shall ensure that any entity that provides phar-
10
macy benefits management services under a 
11
contract with any such health plan or health in-
12
surance coverage does not, directly or indirectly, 
13
receive from a manufacturer of certified insulin 
14
a rebate, reduction in price, or other remunera-
15
tion with respect to such insulin received by an 
16
enrollee in the plan or coverage and covered by 
17
the plan or coverage. 
18
‘‘(B) EXCEPTION.—The requirement under 
19
subparagraph (A) shall not apply to— 
20
‘‘(i) any such reduction in price that 
21
is reflected at the point of sale to the en-
22
rollee; or 
23
‘‘(ii) any remuneration that is a flat 
24
fee-based service fee that a manufacturer 
25
15:51 Nov 02, 2019
H4906
3 
•HR 4906 IH
of such insulin pays to a pharmacy benefit 
1
manager for services rendered to the man-
2
ufacturer that relate to arrangements by 
3
the pharmacy benefit manager to provide 
4
pharmacy benefit management services to 
5
a health plan or health insurance issuer, if 
6
certain conditions established by the Sec-
7
retary are met, including requirements 
8
that the fees are transparent to the health 
9
plan or health insurance issuer. 
10
‘‘(2) APPLICABILITY.—The restriction under 
11
paragraph (1) shall apply with respect to insulin de-
12
scribed in paragraph (1), for which the manufac-
13
turer has certified the list price in accordance with 
14
section 5(b) of the Insulin Price Reduction Act with 
15
respect to— 
16
‘‘(A) any plan year in which the list price 
17
for insulin is certified under section 5(b)(2)(A) 
18
of the Insulin Price Reduction Act; and 
19
‘‘(B) each subsequent plan year during 
20
which the manufacturer limits any increase in 
21
the list price to the price that gave rise to the 
22
restriction under paragraph (1), adjusted by 
23
not more than the price change in the medical 
24
care component of the consumer price index for 
25
15:51 Nov 02, 2019
H4906
4 
•HR 4906 IH
all urban consumers (U.S. city average), as cer-
1
tified under section 5(b)(2)(B) of the Insulin 
2
Price Reduction Act. 
3
‘‘(b) DEDUCTIBLE LIMITATION.—A group health 
4
plan or a health insurance issuer offering group or indi-
5
vidual health insurance coverage shall not apply any de-
6
ductible amount that otherwise is applicable to prescrip-
7
tion drugs with respect to coverage of certified insulin 
8
under such plan or coverage, during the period described 
9
in subsection (a)(2). 
10
‘‘(c) HOLD HARMLESS.—During the period begin-
11
ning on the date a certification is first made under section 
12
5(b)(2)(A) of the Insulin Price Reduction Act and ending 
13
on the last day of the second plan year beginning on or 
14
after such date, a group health plan or a health insurance 
15
issuer offering group or individual health insurance cov-
16
erage shall not, and shall ensure that any entity that pro-
17
vides pharmacy benefits management services under a 
18
contract with such health plan or health insurance cov-
19
erage does not— 
20
‘‘(1) restrict or disadvantage such insulin from 
21
the formulary applicable to the plan or coverage rel-
22
ative to any other insulin or similar formulation; 
23
‘‘(2) impose higher cost-sharing with respect to 
24
such insulin than the cost-sharing that applied with 
25
15:51 Nov 02, 2019
H4906
5 
•HR 4906 IH
respect to the insulin in the year in which the list 
1
price reduction certification was provided under sec-
2
tion 5(b)(2)(A) of the Insulin Price Reduction Act; 
3
‘‘(3) impose any prior authorization require-
4
ments for coverage of such insulin that were not ap-
5
plied during the year in which the list price reduc-
6
tion certification was provided under such section 
7
5(b)(2)(A); or 
8
‘‘(4) establish a step therapy requirement for 
9
such insulin that was not applied during the year in 
10
which the list price reduction certification was pro-
11
vided under such section 5(b)(2)(A). 
12
‘‘(d) DEFINITIONS.—In this section— 
13
‘‘(1) the term ‘certified insulin’ means, with re-
14
spect to a year, insulin that has been certified under 
15
section 5(b) of the Insulin Price Reduction Act for 
16
the year; 
17
‘‘(2) the term ‘insulin’ means any insulin prod-
18
uct approved by the Food and Drug Administration 
19
to improve glycemic control in patients with diabetes 
20
mellitus; 
21
‘‘(3) the term ‘list price’ has the meaning given 
22
the term ‘wholesale acquisition cost’ in section 
23
1847A(c)(6)(B) of the Social Security Act; and 
24
15:51 Nov 02, 2019
H4906
6 
•HR 4906 IH
‘‘(4) the term ‘rebate’ means any discount, 
1
price concession, or fee, other than the fee described 
2
in section (a)(1)(B), the terms of which are fixed at 
3
the time of the sale and disclosed, but which is not 
4
received at the time of the sale.’’. 
5
(b) CONFORMING AMENDMENT.—Paragraph (2) of 
6
section 223(d) of the Internal Revenue Code of 1986 is 
7
amended by redesignating subparagraph (D) as subpara-
8
graph (E) and by inserting after subparagraph (C) the 
9
following new subparagraph: 
10
‘‘(D) SAFE HARBOR FOR ABSENCE OF DE-
11
DUCTIBLE FOR INSULIN.—A plan shall not fail 
12
to be treated as a high deductible health plan 
13
by reason of exempting insulin from any de-
14
ductible pursuant to section 2729A(b) of the 
15
Public Health Service Act during the period de-
16
scribed in section 2729A(a)(2) of such Act.’’. 
17
(c) EFFECTIVE DATE.—The amendments made by 
18
subsections (a) and (b) shall take effect with respect to 
19
plan years beginning on or after January 1, 2022. 
20
SEC. 3. INSULIN PRICE PROTECTIONS UNDER MEDICARE 
21
PART D. 
22
Section 1860D–4 of the Social Security Act (42 
23
U.S.C. 1395w–104) is amended— 
24
15:51 Nov 02, 2019
H4906
7 
•HR 4906 IH
(1) by redesignating the subsection (m) as 
1
added by section 6063(c) of the SUPPORT for Pa-
2
tients and Communities Act (Public Law 115–271) 
3
as subsection (n); and 
4
(2) by adding at the end the following new sub-
5
section: 
6
‘‘(o) LIMITATION ON REBATES, PRICE REDUCTIONS, 
7
OR OTHER REMUNERATION FOR CERTIFIED INSULIN.— 
8
‘‘(1) LIMITATION.— 
9
‘‘(A) IN
GENERAL.—Subject to subpara-
10
graphs (B) and (C), for plan year 2022 and 
11
subsequent plan years, a PDP sponsor and a 
12
Medicare Advantage organization shall ensure 
13
that each prescription drug plan or MA–PD 
14
plan offered by the sponsor or organization, and 
15
any entity that provides pharmacy benefits 
16
management services under a contract with the 
17
prescription drug plan or MA–PD plan offered 
18
by the sponsor or organization, does not, di-
19
rectly or indirectly, receive from a manufacturer 
20
of certified insulin a rebate, reduction in price, 
21
or other remuneration with respect to certified 
22
insulin that is covered by the plan. 
23
‘‘(B) EXCEPTION.—The requirement under 
24
subparagraph (A) shall not apply to— 
25
15:51 Nov 02, 2019
H4906
8 
•HR 4906 IH
‘‘(i) any such reduction in price that 
1
is reflected at the point of sale to the bene-
2
ficiary; or 
3
‘‘(ii) any remuneration that is a flat 
4
fee-based service fee that a manufacturer 
5
of such certified insulin pays to a phar-
6
macy benefit manager for services rendered 
7
to the manufacturer that relate to arrange-
8
ments by the pharmacy benefit manager to 
9
provide pharmacy benefit management 
10
services to a prescription drug plan or 
11
MA–PD plan, if certain conditions estab-
12
lished by the Secretary are met, including 
13
requirements that the fees are transparent 
14
to the prescription drug plan or MA–PD 
15
plan. 
16
‘‘(C) HOLD HARMLESS FOR FIRST 2 YEARS 
17
THAT AN INSULIN IS CERTIFIED.—In the first 
18
2 plan years during which paragraph (2) ap-
19
plies with respect to a certified insulin, a PDP 
20
sponsor and a Medicare Advantage organization 
21
shall not, and shall ensure that any entity that 
22
provides pharmacy benefits management serv-
23
ices under a contract with such sponsor or or-
24
ganization does not— 
25
15:51 Nov 02, 2019
H4906
9 
•HR 4906 IH
‘‘(i) remove such insulin from the for-
1
mulary applicable to the prescription drug 
2
plan or MA–PD plan; 
3
‘‘(ii) impose higher cost-sharing with 
4
respect to such insulin than the cost-shar-
5
ing that applied with respect to the cer-
6
tified insulin in the year in which the list 
7
price reduction certification was provided 
8
under section 5(b)(2)(A) of the Insulin 
9
Price Reduction Act; 
10
‘‘(iii) impose any prior authorization 
11
requirements for coverage of the certified 
12
insulin that were not applied during the 
13
year in which the list price reduction cer-
14
tification was provided under such section 
15
5(b)(2)(A); or 
16
‘‘(iv) establish a step therapy require-
17
ment for the certified insulin that was not 
18
applied during the year in which the list 
19
price reduction certification was provided 
20
under such section 5(b)(2)(A). 
21
‘‘(2) DEFINITIONS.—In this section: 
22
‘‘(A) CERTIFIED INSULIN.—The term ‘cer-
23
tified insulin’ means, with respect to a year, in-
24
15:51 Nov 02, 2019
H4906
10 
•HR 4906 IH
sulin that has been certified under section 5(b) 
1
of the Insulin Price Reduction Act for the year. 
2
‘‘(B) INSULIN.—The term ‘insulin’ means 
3
any insulin product approved by the Food and 
4
Drug Administration to improve glycemic con-
5
trol in patients with diabetes mellitus. 
6
‘‘(C) LIST
PRICE.—The term ‘list price’ 
7
has the meaning given the term ‘wholesale ac-
8
quisition cost’ in section 1847A(c)(6)(B). 
9
‘‘(D) REBATE.—The term ‘rebate’ means 
10
any discount, price concession, or fee, other 
11
than the fee described in paragraph (1)(B), the 
12
terms of which are fixed at the time of the sale 
13
and disclosed, but which is not received at the 
14
time of the sale.’’. 
15
SEC. 4. APPLICABILITY OF PRE-LIST PRICE REDUCTION 
16
AMP 
TO 
MEDICAID 
MINIMUM 
REBATE 
17
AMOUNTS. 
18
Section 1927(c) of the Social Security Act (42 U.S.C. 
19
1396r–8(c)) is amended— 
20
(1) in paragraph (1)(A), in the matter pre-
21
ceding clause (i), by inserting ‘‘and paragraph (5)’’ 
22
after ‘‘paragraph (2)’’; 
23
15:51 Nov 02, 2019
H4906
11 
•HR 4906 IH
(2) in paragraph (3)(A), in the matter pre-
1
ceding clause (i), by inserting ‘‘and paragraph (5)’’ 
2
after ‘‘subparagraph (C)’’; and 
3
(3) by adding at the end the following new 
4
paragraph: 
5
‘‘(5) SPECIAL
RULE
FOR
DETERMINING
MIN-
6
IMUM BASIC REBATES FOR INSULIN.— 
7
‘‘(A) IN
GENERAL.—In determining the 
8
amount of the rebate specified in this sub-
9
section for a dosage form and strength of a cov-
10
ered outpatient drug described in subparagraph 
11
(B) for any rebate period occurring after April 
12
30, 2020, paragraph (1)(A)(ii)(II) or paragraph 
13
(3)(A)(i) (as applicable) shall be applied by sub-
14
stituting— 
15
‘‘(i) the pre-reduction average manu-
16
facturer price (as defined in subparagraph 
17
(C)) for the dosage form and strength of 
18
the drug for the rebate period; for 
19
‘‘(ii) the average manufacturer price 
20
for the dosage form and strength of the 
21
drug for the rebate period. 
22
‘‘(B) DRUGS DESCRIBED.—A covered out-
23
patient drug is described in this subparagraph 
24
for a rebate period if the drug is insulin for 
25
15:51 Nov 02, 2019
H4906
12 
•HR 4906 IH
which, throughout such rebate period, the man-
1
ufacturer has certified the list price for each 
2
dosage form and strength of such drug in ac-
3
cordance with section 5(b) of the Insulin Price 
4
Reduction Act. 
5
‘‘(C) PRE-REDUCTION AVERAGE MANUFAC-
6
TURER
PRICE.—For purposes of this para-
7
graph, the term ‘pre-reduction average manu-
8
facturer price’ means, with respect to each dos-
9
age form and strength of a covered outpatient 
10
drug described in subparagraph (B) and a re-
11
bate period— 
12
‘‘(i) the average manufacturer price 
13
for such drug for the calendar quarter be-
14
ginning July 1, 2019; increased by 
15
‘‘(ii) the percentage by which the con-
16
sumer price index for all urban consumers 
17
(United States city average) for the month 
18
before the month in which the rebate pe-
19
riod begins exceeds such index for Sep-
20
tember 2019.’’. 
21
SEC. 5. LIST PRICE DATA SUBMISSIONS. 
22
(a) INITIAL SUBMISSION.— 
23
(1) IN
GENERAL.—Not later than April 30, 
24
2020, any manufacturer of insulin wishing to receive 
25
15:51 Nov 02, 2019
H4906
13 
•HR 4906 IH
certification under this section shall submit to the 
1
Secretary— 
2
(A) data on the list price of any insulin 
3
manufactured by the manufacturer during the 
4
period beginning on January 1, 2000 (or the 
5
first date on which such manufacturer begins 
6
manufacturing such insulin), through the list 
7
price applicable at the time of the report; and 
8
(B) a certification that such data is accu-
9
rate. 
10
(2) LATER
SUBMISSIONS.—Any manufacturer 
11
of insulin that does not submit the information de-
12
scribed in paragraph (1) by the date described in 
13
such paragraph may later submit the information 
14
described in subparagraphs (A) and (B) of para-
15
graph (1) to the Secretary. Such a manufacturer 
16
who submits such information pursuant to this para-
17
graph is eligible to certify its list price for the appli-
18
cable insulin under subsection (b)(2)(A)(ii) with re-
19
spect to the first plan year that begins at least 15 
20
months after the date of submission under this para-
21
graph. 
22
(b) ANNUAL PRICE CERTIFICATION.— 
23
(1) IN GENERAL.—Any manufacturer of insulin 
24
who submits information in accordance with sub-
25
02:08 Nov 05, 2019
H4906
14 
•HR 4906 IH
section (a) is eligible for certification under this sub-
1
section. 
2
(2) REQUIREMENTS.— 
3
(A) FIRST CERTIFICATION.— 
4
(i) INITIAL ELIGIBILITY FOR CERTIFI-
5
CATION.—A manufacturer of insulin who 
6
submits 
information 
under 
subsection 
7
(a)(1) is considered certified under this 
8
subsection for plan year 2022 if such man-
9
ufacturer, not later than September 30, 
10
2020, submits to the Secretary a certifi-
11
cation that the manufacturer reduced its 
12
list price for insulin to an amount that is 
13
no greater than the list price for the same 
14
insulin that applied as of July 1, 2006. 
15
(ii) LATER CERTIFICATION.—A manu-
16
facturer of insulin that submitted informa-
17
tion under subsection (a)(2) not later than 
18
September 30 of the calendar year that is 
19
2 years prior to the applicable plan year, 
20
is considered certified under this sub-
21
section for the applicable plan year if such 
22
manufacturer submits to the Secretary a 
23
certification, not later than September 30 
24
of such calendar year, that the manufac-
25
15:51 Nov 02, 2019
H4906
15 
•HR 4906 IH
turer reduced its list price for insulin to 
1
the amount that is no greater than the list 
2
price for the same insulin that applied as 
3
of July 1, 2006, increased by not more 
4
than the rate by which the medical care 
5
component of the consumer price index for 
6
all urban consumers (U.S. city average) in-
7
creased between September 30, 2020, and 
8
the date on which the certification is sub-
9
mitted. 
10
(B) SUBSEQUENT
CERTIFICATION.—For 
11
plan year 2023 and each plan year thereafter, 
12
a manufacturer of insulin who previously sub-
13
mitted a certification under clause (i) or (ii) of 
14
subparagraph (A) is considered certified under 
15
this subsection for the applicable plan year if 
16
such manufacturer submits, not later than Sep-
17
tember 30 of the calendar year that is 2 years 
18
prior to the applicable plan year, a certification 
19
that the manufacturer did not increase the list 
20
price for insulin previously certified under 
21
clause (i) or (ii) of subparagraph (A), by more 
22
than the rate by which the medical care compo-
23
nent of the consumer price index for all urban 
24
consumers (U.S. city average) increased since 
25
02:08 Nov 05, 2019
H4906
16 
•HR 4906 IH
the initial certification under such clause (i) or 
1
(ii). 
2
(3) SPECIAL RULE FOR CERTAIN INSULIN.— 
3
(A) IN GENERAL.—In the case of a manu-
4
facturer of insulin that did not manufacture a 
5
particular insulin in 2006, such manufacturer 
6
may be certified under this subsection with re-
7
spect to such insulin by submitting information 
8
under paragraph (2)(A) certifying that the list 
9
price of such insulin is no greater than the 
10
weighted average list price, in 2006, of, as ap-
11
plicable— 
12
(i)(I) all short-acting insulins; 
13
(II) all rapid-acting insulins; or 
14
(III) all long-acting insulins; or 
15
(ii) such other insulin categories, as 
16
the Secretary determines appropriate. 
17
(B) INCREASE.—The weighted averages 
18
under subparagraph (A) shall be increased in 
19
accordance with paragraph (2)(A)(ii), as appli-
20
cable. 
21
(4) APPLICATION TO AUTHORIZED GENERIC IN-
22
SULIN.—In the case of an insulin that is classified 
23
as an authorized generic drug, as defined in section 
24
505(t)(3) of the Federal Food, Drug, and Cosmetic 
25
02:08 Nov 05, 2019
H4906
17 
•HR 4906 IH
Act (21 U.S.C. 355(t)(3)), the manufacturer of such 
1
insulin may be certified under this section by sub-
2
mitting information under paragraph (1)(A) certi-
3
fying that the list price of such authorized generic 
4
insulin is no greater than the list price, as of July 
5
1, 2006, of the listed drug insulin product upon 
6
which the authorized generic drug was based under 
7
section 505(t) of the Federal Food, Drug, and Cos-
8
metic Act. The certification pursuant to this para-
9
graph applies only to the authorized generic drug in-
10
sulin, and does not apply with respect to the applica-
11
ble listed drug insulin. 
12
(c) AUDITS AND PENALTIES.—The Inspector General 
13
of the Department of Health and Human Services may 
14
audit the financial records and other relevant records of 
15
any manufacturer submitting data under subsections (a) 
16
and (b), and any manufacturer or officer, director, agent, 
17
or managing employee of such manufacturer that know-
18
ingly submits false or incomplete data shall be subject to 
19
a civil penalty for each insulin for which false or incom-
20
plete data are submitted in an amount not to exceed the 
21
greater of— 
22
(1) an amount equal to 2 times the total 
23
amount of rebates paid by the manufacturer to 
24
State Medicaid plans for the insulin for rebate peri-
25
02:08 Nov 05, 2019
H4906
18 
•HR 4906 IH
ods occurring in calendar year 2018 under section 
1
1927 of the Social Security Act (42 U.S.C. 1396r– 
2
8); or 
3
(2) an alternative amount to be determined by 
4
the Secretary. 
5
(d) DEFINITIONS.—In this section— 
6
(1) the term ‘‘insulin’’ means any insulin prod-
7
uct approved by the Food and Drug Administration 
8
to improve glycemic control in patients with diabetes 
9
mellitus; 
10
(2) the term ‘‘list price’’ has the meaning given 
11
the term ‘‘wholesale acquisition cost’’ in section 
12
1847A(c)(6)(B) of the Social Security Act (42 
13
U.S.C. 1395w–3a(c)(6)(B)); and 
14
(3) the term ‘‘Secretary’’ means the Secretary 
15
of Health and Human Services. 
16
Æ 
15:51 Nov 02, 2019
H4906
